1602 related articles for article (PubMed ID: 7604788)
21. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
22. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
Greten H; Beil FU; Schneider J; Weisweiler P; Armstrong VW; Keller C; Klör HU; von Hodenberg E; Weidinger G; Eskötter H
Am J Med; 1994 Jun; 96(6A):55S-63S. PubMed ID: 8017468
[TBL] [Abstract][Full Text] [Related]
23. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
[TBL] [Abstract][Full Text] [Related]
24. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group.
Dallongeville J; Fruchart JC; Pfister P; Bard JM
J Intern Med Suppl; 1994; 736():95-101. PubMed ID: 7986315
[TBL] [Abstract][Full Text] [Related]
25. Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-I. European Fluvastatin Study Group.
Dallongeville J; Fruchart JC; Pfister P; Bard JM
Am J Med; 1994 Jun; 96(6A):32S-36S. PubMed ID: 8017464
[TBL] [Abstract][Full Text] [Related]
26. Effects of fluvastatin on human biliary lipids.
Tazuma S; Ohya T; Mizuno T; Takizawa I; Kunita T; Takata K; Hayashi K; Hino F; Tokumo H; Watanabe T
Am J Cardiol; 1995 Jul; 76(2):110A-113A. PubMed ID: 7604783
[TBL] [Abstract][Full Text] [Related]
27. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of treatment with low-dose fluvastatin in hypercholesterolemic renal transplant recipients.
Akiyama T; Ishii T; Imanishi M; Nishioka T; Matsuura T; Kurita T
Transplant Proc; 2001 May; 33(3):2115-8. PubMed ID: 11377469
[No Abstract] [Full Text] [Related]
29. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
Leitersdorf E; Eisenberg S; Eliav O; Friedlander Y; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Wurm M
Circulation; 1993 Apr; 87(4 Suppl):III35-44. PubMed ID: 8462179
[TBL] [Abstract][Full Text] [Related]
30. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
Alaupovic P; Heinonen T; Shurzinske L; Black DM
Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
[TBL] [Abstract][Full Text] [Related]
31. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.
Eliav O; Schurr D; Pfister P; Friedlander Y; Leitersdorf E
Am J Cardiol; 1995 Jul; 76(2):76A-79A. PubMed ID: 7604804
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.
Sasaki S; Nakagawa M; Nakata T; Endo N; Miyao K; Kitamura K; Fukuyama M; Kitani T; Yamada C
Cardiology; 1997; 88(2):160-5. PubMed ID: 9096917
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.
Ballantyne CM; Pazzucconi F; Pintó X; Reckless JP; Stein E; McKenney J; Bortolini M; Chiang YT
Clin Ther; 2001 Feb; 23(2):177-92. PubMed ID: 11293552
[TBL] [Abstract][Full Text] [Related]
34. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia.
Li PK; Mak TW; Chan TH; Wang A; Lam CW; Lai KN
Transplantation; 1995 Oct; 60(7):652-6. PubMed ID: 7570971
[TBL] [Abstract][Full Text] [Related]
35. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.
März W; Scharnagl H; Abletshauser C; Hoffmann MM; Berg A; Keul J; Wieland H; Baumstark MW
Circulation; 2001 Apr; 103(15):1942-8. PubMed ID: 11306521
[TBL] [Abstract][Full Text] [Related]
36. Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia.
Isaacsohn JL; LaSalle J; Chao G; Gonasun L
Clin Ther; 2003 Mar; 25(3):904-18. PubMed ID: 12852707
[TBL] [Abstract][Full Text] [Related]
37. Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.
Kellick KA; Burns K; McAndrew E; Haberl E; Hook N; Ellis A
Am J Cardiol; 1995 Jul; 76(2):62A-64A. PubMed ID: 7604801
[TBL] [Abstract][Full Text] [Related]
38. Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, suppresses very low-density lipoprotein secretion in puromycin aminonucleoside-nephrotic rats.
Moritomo Y; Hirano T; Ebara T; Kurokawa M; Naito H; Furukawa S; Nagano S
Nephron; 1994; 67(2):218-25. PubMed ID: 8072613
[TBL] [Abstract][Full Text] [Related]
39. Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database.
Peters TK; Muratti EN; Mehra M
Am J Med; 1994 Jun; 96(6A):79S-83S. PubMed ID: 8017471
[TBL] [Abstract][Full Text] [Related]
40. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
